Publication Type:

Journal Article

Source:

Current Pharmaceutical Design, Bentham Science Publishers B.V., Volume 23, Number 24, p.3550-3566 (2017)

URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85033211492&doi=10.2174%2f1381612823666170601105439&partnerID=40&md5=897dedd7fe546aa57878a88fa3f191cb

Keywords:

adenosine, albumin conjugate, alopecia, anemia, angiogenesis, antigen presenting cell, antiinflammatory activity, blood toxicity, CD1d antigen, cell adhesion molecule, cell differentiation, cell maturation, colloid, cytokine, cytokine production, drug absorption, drug distribution, drug dose reduction, drug efficacy, drug elimination, drug excretion, drug exposure, drug formulation, drug mechanism, drug metabolism, drug penetration, drug structure, drug targeting, drug withdrawal, environmental factor, fatigue, gamma interferon inducible protein 10, gastrointestinal atrophy, gastrointestinal disease, gel, headache, heredity, human, hydrogel, immunomodulation, interleukin 1, interleukin 15, interleukin 17, interleukin 17F, interleukin 18, interleukin 20, interleukin 21, interleukin 6, interleukin 8, keratinocyte, kidney dysfunction, liposomal delivery, liposome, lipoxygenase, liver biopsy, liver dysfunction, liver toxicity, low drug dose, lung toxicity, macrophage inflammatory protein 3alpha, matrix metalloproteinase, maximum plasma concentration, megalocytosis, methotrexate, microemulsion, monocyte chemotactic protein 1, nanoparticle, nausea, niosome, oxidation reduction state, pancytopenia, pathogenesis, priority journal, prostaglandin synthase, psoriasis, RANTES, rash, review, rheumatoid arthritis, risk factor, spermidine, spermine, T lymphocyte, time to maximum plasma concentration, tumor necrosis factor, unindexed drug, vasculotropin

Abstract:

Our review is focused on the use of methotrexate in drug therapy of two autoimmune diseases, psoriasis and rheumatoid arthritis (RA). The article describes the pathogenesis of psoriasis and RA, the role of methotrexate in the treatment of these diseases with more focused review on the mechanism behind the clinical benefits of methotrexate therapy. Methotrexate due to its cytotoxic, anti-inflammatory and immune modulatory activities provides clinical benefits in the therapy of the selected diseases. This review also gives a panorama of the problems associated with the use of methotrexate in the selected diseases and the guidelines provided by FDA for its safe use. The novel colloidal drug delivery systems of methotrexate, with particular emphasis on advantages offered by liposomal formulation, niosomal gel, hydrogel, albumin conjugates, nanoparticles and nano structured lipid carriers in psoriasis and RA are also reviewed. It seemed that the use of newer colloidal carriers with improved skin permeability by minimizing its systemic availability will be a useful strategy to reduce the toxic effects of the drug in psoriatic patients. In rheumatoid arthritis patients, the development of newer therapeutic strategies using appropriate targeting ligands that specifically deliver the drug to the inflamed joint space will help to overcome its toxic effects by minimizing the systemic exposure. © 2017 Bentham Science Publishers.

Notes:

cited By 1

Cite this Research Publication

P. Rajitha, Biswas, R., Sabitha, M., and Jayakumar, R., “Methotrexate in the treatment of psoriasis and rheumatoid arthritis: Mechanistic insights, current issues and novel delivery approaches”, Current Pharmaceutical Design, vol. 23, pp. 3550-3566, 2017.

207
PROGRAMS
OFFERED
6
AMRITA
CAMPUSES
15
CONSTITUENT
SCHOOLS
A
GRADE BY
NAAC, MHRD
8th
RANK(INDIA):
NIRF 2018
150+
INTERNATIONAL
PARTNERS